Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | AKT2 | P31751 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 6/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | PLG | P00747 | 2/20 | 0.38 |
| ▸ | KLK1 | P06870 | 2/20 | 0.38 |
| ▸ | KLK6 | Q92876 | 2/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3791657 | 0.85 | AKT2 (0.49) | HRH3AKT2BACE1CD274TAAR1 | |
| SCHEMBL3784856 | 0.84 | HTR7 (0.44) | TAAR1CSNK2A1DPP4PLG | |
| SCHEMBL3786898 | 0.83 | DPP4 (0.59) | CD274TAAR1CSNK2A1DPP4CNR1 | |
| SCHEMBL20530624 | 0.80 | MAP2K4 (0.47) | CD274TAAR1DPP4 | |
| SCHEMBL22400156 | 0.79 | HRH3 (0.48) | HRH3AKT2BACE1CD274TAAR1 | |
| SCHEMBL21859425 | 0.79 | HRH3 (0.43) | HRH3AKT2BACE1CD274TAAR1 | |
| SCHEMBL27936615 | 0.78 | HRH3 (0.46) | HRH3AKT2BACE1CD274TAAR1 | |
| SCHEMBL260102 | 0.75 | HRH3 (0.74) | HRH3AKT2BACE1TAAR1CYP1A2 | |
| SCHEMBL3789540 | 0.75 | HRH3 (0.52) | HRH3AKT2BACE1CD274TAAR1 | |
| SCHEMBL21725464 | 0.74 | HRH3 (0.42) | HRH3AKT2BACE1CD274TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | HRH3 169/4885AKT2 3144/4885BACE1 925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.